chronic bronchitis Emphysema
Conditions
Interventions
Intake sugarsolution
Sponsors
Medisch Universitair Ziekenhuis Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Diagnosis of COPD stages I-IV as defined by the (GOLD)(7); - At admission the diagnosis AE-COPD as defined by the (GOLD)(7); - Both male and female, age-range from 40 years; - Hypoxemia of PaO2
Exclusion criteria
Exclusion criteria: *Participation in any other study involving investigational or marketed products concomitantly or within two weeks prior to entry into the study; *Any kind of acute gastro-intestinal complaints or active gastro-intestinal disease; *The presence of decompensated hearth failure, assessed by analyses of plasma pro-BNP levels; *Use of NSAIDin the past 48 hours before the tests (ibuprofen, naproxen, meloxicam, diclofenac) with the exception of acetylsalicic acid
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main study parameters: intestinal damage and permeability, which will be analysed by several markers in urine and plasma. - Multi-sugar permeability test The sugar mixture contains lactulose, sucralose, rhamnose and erythritol. Lactulose and rhamnose are often used as a marker for small intestinal permeability since they are degraded by the bacterial flora in the colon. Sucralose and erythritol can be used as a marker for whole gut permeability since they resist colonic bacterial fermentation. In combination with the lactulose/rhamnose data they provide an insight in colon permeability. - Determination of intestinal cell damage Intestinal fatty acid-binding protein (IFABP) is a small cytosolic protein present in absorptive epithelial cells, and is expressed in all parts of the intestine (small intestine and colon, but with the highest expression in the jejunum). In case of intestinal cell damage, these proteins leak from the cells into the circulation and can be measured in plasma. - Determination of epithelial tight junction proteins in blood and urine The loss of tight junction protein claudin 3 in the intestinal epithelium correlates with the appearance of the proteins into plasma and urine. | — |
Secondary
| Measure | Time frame |
|---|---|
| In venous blood, additional markers will be analysed: Inflammatory markers Plasma markers of inflammation will be measured to test a correlation between systemic inflammatory markers and markers of intestinal permeability. | — |
Countries
Netherlands
Outcome results
None listed